- Home
- NMT vs VERU Comparison
NMT vs VERU Comparison
Compare NMT & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMT
- VERU
- Stock Information
- Founded
- NMT 1993
- VERU 1971
- Country
- NMT United States
- VERU United States
- Employees
- NMT N/A
- VERU N/A
- Industry
- NMT Finance/Investors Services
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- NMT Finance
- VERU Health Care
- Exchange
- NMT Nasdaq
- VERU Nasdaq
- Market Cap
- NMT 110.6M
- VERU 75.1M
- IPO Year
- NMT N/A
- VERU 1990
- Fundamental
- Price
- NMT $11.77
- VERU $0.49
- Analyst Decision
- NMT
- VERU Strong Buy
- Analyst Count
- NMT 0
- VERU 4
- Target Price
- NMT N/A
- VERU $4.00
- AVG Volume (30 Days)
- NMT 19.1K
- VERU 2.2M
- Earning Date
- NMT 01-01-0001
- VERU 02-13-2025
- Dividend Yield
- NMT 3.21%
- VERU N/A
- EPS Growth
- NMT N/A
- VERU N/A
- EPS
- NMT N/A
- VERU N/A
- Revenue
- NMT N/A
- VERU $16,886,419.00
- Revenue This Year
- NMT N/A
- VERU N/A
- Revenue Next Year
- NMT N/A
- VERU $30.16
- P/E Ratio
- NMT N/A
- VERU N/A
- Revenue Growth
- NMT N/A
- VERU 22.46
- 52 Week Low
- NMT $9.05
- VERU $0.48
- 52 Week High
- NMT $10.93
- VERU $1.92
- Technical
- Relative Strength Index (RSI)
- NMT 46.08
- VERU 39.20
- Support Level
- NMT $11.85
- VERU $0.49
- Resistance Level
- NMT $11.89
- VERU $0.62
- Average True Range (ATR)
- NMT 0.09
- VERU 0.04
- MACD
- NMT -0.02
- VERU 0.00
- Stochastic Oscillator
- NMT 12.96
- VERU 12.97
About NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes by investing in a portfolio of municipal obligations issued by state and local government authorities within a single state or certain U.S. territories.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.